Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
14.82
+0.24 (1.65%)
At close: May 12, 2025, 4:00 PM
14.01
-0.81 (-5.47%)
After-hours: May 12, 2025, 4:44 PM EDT
Edgewise Therapeutics Employees
Edgewise Therapeutics had 110 employees as of December 31, 2024. The number of employees increased by 22 or 25.00% compared to the previous year.
Employees
110
Change (1Y)
22
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,328,055
Market Cap
1.56B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 110 | 22 | 25.00% |
| Dec 31, 2023 | 88 | 29 | 49.15% |
| Dec 31, 2022 | 59 | 28 | 90.32% |
| Dec 31, 2021 | 31 | 12 | 63.16% |
| Dec 31, 2020 | 19 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EWTX News
- 4 days ago - Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 4 weeks ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 - Benzinga
- 5 weeks ago - Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On - Seeking Alpha
- 5 weeks ago - Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study - Benzinga
- 5 weeks ago - Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock - PRNewsWire
- 5 weeks ago - Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - PRNewsWire
- 6 weeks ago - Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - PRNewsWire
- 2 months ago - Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference - Business Wire